CTRI/2018/06/014434尚未招募未知
Evaluation of a Web Portal for Cancer Awareness for General Population and Level 1 Care Providers
ICMR0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •All the adults aged >= 18 years residing in the selected village for at least six months
- •would be eligible to be included in the study. All the community health workers involved in provision of
- •health services posted in the selected villages including health education through Behaviour Change
- •Communication (BCC) strategy etc would also be eligible for participation in the study.
排除标准
- •Below 18 years of age
研究者
相似试验
招募中
不适用
CareCN: A phase I/II, open-label, study to evaluate the safety and efficacy of an intravenous injection of GNT0003 (Adeno-associated Viral Vector expressing the UGT1A1 transgene) in patients with severe Crigler-Najjar syndrome requiring phototherapyCrigler-Najjar Syndrome10027424NL-OMON52580Généthon5
招募中
1 期
Gene Therapy for Crigler-Najjar Syndromesevere Crigler-Najjar syndrome in patients requiring phototherapyMedDRA version: 20.0Level: PTClassification code: 10011386Term: Crigler-Najjar syndrome Class: 100000004850CTIS2023-507007-60-00Genethon17
招募中
不适用
A Phase 1, Open-label Clinical Study to Assess the Pharmacokinetics (Distribution, Metabolism,;and Excretion) of 14C-Vosaroxin in Patients with Advanced Solid Tumorsadvanced solid tumors (ie, breast, lung, head/neck,colorectal, melanoma, and sarcoma)Solid tumorsNL-OMON42076Sunesis Pharmaceuticals, Inc.6
进行中(未招募)
不适用
A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese SubjectsPneumococcal InfectionMedDRA version: 17.1Level: PTClassification code 10061353Term: Pneumococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-004180-20-Outside-EU/EEAPfizer Inc72
未知
1 期
Phase 1 study of DS-8895aAdvanced solid tumor that is refractory to standard treatment, or for which no standard treatment is available.JPRN-jRCT2080222257DAIICHISANKYO Co.,Ltd.38
